Curriculum

La Dr.ssa Grandi si e' laureata e presso l'Universita' di Ferrara in Biologia nel 1996. Nel 2001 riceve il Dottorato di ricerca in Biochimica anno in cui accetta una posizione come post-doc presso il "Molecular Neurogenetics Department" al the Massachusetts General Hospital - Harvard Medical School di Boston. Nel 2005 diventa Assistant professor presso il Dipartimento di Neurochirurgia dell'Universita' di Pittsburgh. Dall'aprile 2013 e' ricercatore a contratto presso l'Universita' di Ferrara.

Academic

 

04/2013-present          Assistant Professor, Department Science of Life and Biotechnologies (SVEB) , University of Ferrara, Italy

 

04/2005-present                       Assistant Professor, Department of Neurological Surgery, University of Pittsburgh

 

12/2004-03/2005            Researcher Associate,  Department of Neurological Surgery, University of Pittsburgh

 

01/2002-11/2004        Post-doc (Neurology) Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA

 

05/2001-12/2001         Fellow Research (Neurology) Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA

 

12/1997-04/2001         Research project working on amplicon vectors as a novel approach to HIV-1 vaccine development, Department of Experimental and Diagnostic Medicine (Section of Microbiology), University of Ferrara, Italy

 

01/1997-12/1997         M. Sc. Training in Genetic, at the Department of Experimental and Diagnostic Medicine (Section of Genetics), University of Ferrara, Italy

 

03/1994-12/1996         Undergraduate student at the Department of Experimental and Diagnostic Medicine (Section of Microbiology), University of Ferrara, Italy, B.Sc. training in Virology

 

 

Professsional Activities

2005-2010                   Assistant Editor for the Nature Group Journal, Gene Therapy

2010-present               ASGCT webtaskforce

2011-present               ASGCT Cancer Gene & Cell Therapy Commette

2012                            Founder of ACAREF: Allied Community Ataxia Research Foundation

Honors:

1996       B.Sc. in Biology: degree with 110/110 cum laude from University of Ferrara;

1997       M.Sc. in Genetic: degree with distinction;

2001       Ph.D degree with optimum from University of Ferrara;

2001       Only fellowship for US study from University of Ferrara.

2005        travel award for the best oral presentation at the International Herpesvirus Workshop, Turku, Finland.

2012         Scientist of the month (march) from American Society for Gene and Cell therapy.

Pubblicazioni

  1. Uchida H, Chan J, Shrivastava I, Reinhart B, Grandi P, Glorioso JC, Cohen JB. Novel mutations in gB and gH circumvent the requirement of known gD Receptors in herpes Simplex Virus 1 Entry and cell-to-cell spread. J Virol. 2013 Feb;87(3):1430-42. doi: 10.1128/JVI.02804-12. Epub 2012 Nov 14.
  2. Bonnie Reinhart, Lucia Mazzacurati, Adriana Forero, Chang-Sook Hong, Junichi Eguchi, Hideho Okada, Wendy Fellow, Ajay Niranjan, Justus Cohen, J. C. Glorioso and Paola Grandi.  Inhibition of Indoleamine-2,3-Dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Advances in Virology. 2012; 2012:815465
  3. Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Gene Ther. 2010 Sep;17(9):655-63. Epub 2010 May 28.
  4. Hiroaki Uchida, Marco Marzulli, William F. Goins, Janet Chan, Chang-Sook Hong, Lucia Mazzacurati, Ji Y. Yoo, Amy Haseley, Hiroshi Nakashima, Kenji Nakano, Hyunjung Baek, Heechung Kwon, Izumi Kumagai, Masahide Kuroki, Balveen Kaur, E. Antonio Chiocca, Paola Grandi, Justus B. Cohen, and Joseph C. Glorioso. Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-Retargeted Oncolytic Herpes Simplex Virus. Mol. Therapy 2013 Mar;21(3):561-9.
  5. Uchida H, Chan J, Goins WF, Grandi P, Kumagai I. Cohen JB, and Glorioso, JC. A double mutation in glycoprotein B compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol. Dec; 84(23): 12200-9, 2010.
  6. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. Oct; 17(10): 1200-5, 2010.
  7. Frampton AR Jr, Uchida H, von Einem J, Goins WF, Grandi P, Cohen JB, Osterrieder N, Glorioso JC. Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Vet Microbiol. 2010 Feb 24;141(1-2):12-21. Epub 2009 Aug 8.
  8. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009 Apr;9(4):505-17
  9. Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P, Cohen JB, Glorioso JC. Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. J Virol. 2009 Apr;83(7):2951-61.
  10. H. Li, D. Krisky, P. Grandi, R. Baskaran, J. C. Glorioso . HSV-1 ICP0 activates Chk2 to induce G2/M arrest and to enhance virus growth. Virology. 2008 May 25;375(1):13-23
  11. Bozac, Berto E., VasquezF., Grandi P., Caputo A., Mnaservigi R., Ensoli B., Marconi P. Expression of Human Immunodeficiency Virus Type 1 tat from a replication-deficient herpes simplex vector induces antigen-specific T cell responses. Vaccine. 2006 Nov 30;24(49-50):7148-58. Epub 2006 Jul 12.
  12. Grandi P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M. Targeting HSV-1 virions for specific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. (2006) Mol. Therapy. 13: 168
  13. Trevor McKee1 , Paola Grandi1 , Wilson Mok, George Alexandrakis, Numpon Insin, John P. Zimmer, Moungi G. Bawendi, Yves Boucher Xandra O. Breakefield and Rakesh K. Jain. Degradation of fibrillar collagen within solid tumors improves the efficacy of oncolytic viral therapy (2006). Cancer Research 66 (5): 2509-13 1 authors contributed equally
  14. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1 virions engineered for specific binding to cell surface receptor (2004) Mol. Therapy, 9: 419-27.
  15. Grandi P., Spear M., Breakefield X., Wang S. Targeting HSV-1 vectors (2004). Methods, 33:179-186.
  16. Spear M., Schuback D., Miyata K., Grandi P., Sun F., Yoo L., Nguyen A., Brandt C.R., Breakefield X. HSV-1 amplicon peptide display vector (2003). Journal of Virological Methods; 107: 71-79.
  17. Garrafa E., Argnani R, Marconi P., Grandi P., Zerbinati A., Bozac A., Berto E., Gardo G., Fugagnoli S., Catalano C., Grossi M.P., Balboni P.G., Manservigi R. Virus erpetici come vettori vaccinali. (2003). L’Igiene Moderna 119: 251-266.
  18. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1 amplicon vector engineered for specific binding to pseudo His-tag receptor. (2002) Mol. Ther. 5: 320.
  19. Caselli E., Grandi P., Argnani R., Balboni P.G., Braga F. and Manservigi R. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB1 induce a protective immune response against HSV-1 infection and establishment of latency (2001). Intervirology; 44: 1-7.
  20. Monini, P., de Lellis L, Rimesi, P., GRANDI P., Franco M, Leone L, Rosso R, Rossi T., Aiuti F, Ledi G. L., Ensoli, B., Cassai, E (1997). Presence of HHV-8 DNA in semen of inmmunocompetent HIV-negative individuals from different geographical areas in Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, ISSN: 1077-9450

 

Book Chapters:

 

  1. Grandi, P., Bein, K., Hadjipanayis, C. G., Wolfe, D., Breakefield, X. O. Glorioso, J.C. “Application of HSV-1 Vectors to the Treatment of Cancer”. "Viral Therapy of Cancer"Book, edited by Kevin Harrington, Hardev Pandha and Richard Vile (April 2008).
  2. Kohn, D.B., Carter, B., Glorioso, J.C. , Grandi P. “Gene Therapy and Viruses”. Clinical Virology. Chapter 20. 2008

 

Presentation and Invited Lectures

Monini P., de Lellis L., Lenette E. T., Rimessi P., GRANDI P., Franco M., Leone P., Lodi G.L., Rossi T., Levy J. A., Rezza G., Cassai E., Ensoli B (1997). PCR detection of HHV-8 DNA in sperm and HHV-8 antibodies detection in immunocompetent individuals from Italy. In: Acts of “Second International Conference on Human Herpesviruses 6, 7 and 8

 

Monini P., de Lellis L., Rimessi P., GRANDI P., Franco M., Leone L., Rosso R., Rossi T., Aiuti F., Lodi G. L., Ensoli B. and Cassai E (1997). Presence of HHV-8 DNA in semen of immunocompetent HIV-negative individuals from different geographical areas in Italy. In: Acts of “National AIDS Malignancy Conference". Bethesda, Marylan, 28-30 April 1997

 

Caselli E, Balboni PG, Incorvaia C, Parmeggiani F, Borsato GM, Bozzini R, GRANDI P., Grossi MP, Manservigi R. (1999). Nuovi approcci per lo sviluppo di un vaccino anti-HSV-1: applicazione ed efficacia dell'immunizzazione genetica e/o perioculare basate sulla gB1s nel coniglio. . In: CNB3 - 3° Congresso Nazionale Biotecnologie. Urbino, Italy, 1-3 luglio 1999Consorzio Interuniversitario Biotecnologie, p. 78-78

 

Secchiero P., Bozzini P., GRANDI P., Balboni P.G., Caselli E., Argnani R., Colle V., Manservigi R (1999). La proteina VP22 del virus dell’herpes: un nuovo modello per la terapia genica anti-HIV-1. In: 3° Congresso del Consorzio Interuniversitario delle Biotecnologie

 

GRANDI P., Secchiero P., Balboni PG e Manservigi R (2000). La proteina VP22 del virus dell’Herpes: un nuovo modello per la terapia genica anti HIV-1. In: 28° Congresso Nazionale Società Italiana di Microbiologia

 

Grandi PVettori ampliconi e VP22: un nuovo sistema di delivery basato sul virus  dell’Herpes simplex.       University of Ferrara, Italy, 10 December 20

 

GRANDI P., Secchiero P, Balboni PG, Zerbinati A, Brewis N, O’Hare P, Manservigi R. (2001). HSV-1 VP22 as a gene therapy approach for HIV. MOLECULAR THERAPY, ISSN: 1525-0024

 

Manservigi R., Marconi P., Argnani R., GRANDI P., Balboni P.G (2001). Amplicon Vectors as a novel approach to HIV-1 vaccine development. Acts of . In: Third National Research Program on AIDS

Grandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, MGH Neuroscience Dept. 10 April 2002

 

Grandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, Harvard Medical School Neuroscience Dept. 25 October 2002

 

Božac A., Berto E., Garrafa E., Gardo G., Boccafogli L., Xausa M., Gavioli R., GRANDI P., Manservigi R., Marconi P.C. (2002). Replication defective HSV-1 vectors - a novel anti-tat vaccination strategy. In: 7th European Conference on Experimental AIDS Research-ECEAR

 

GRANDI P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X (2002). HSV-1 amplicon vector engineered for specific binding to pseudo His-tag receptor. MOLECULAR THERAPY, ISSN: 1525-0024

 

Bozac A., Berto E., Garrafa E., Gardo G., Xausa M., Boccafogli L., Gavioli R., GRANDI P., Manservigi R., Marconi P. (2002). Vettori erpetici non replicativi – vaccini innovativi contro tat. . In: 10th Congresso Nazionale S.I.M.M.O.C

 

 

Grandi P. HSV-1 amplicon vector engineered for specific binding to pseudo his-tag receptor. Boston, Neurosurgery Dept. 8 January 2003

 

Grandi P. Sequential localization of two Herpes simplex virus tegument proteins to puntcate nuclear dots adjacent to ICP0 domains. Boston, Harvard Medical School, Molecular Neurogenetics Dept. 6 June 2003

 

GRANDI P., Samuel Wang, Deborah Schuback, Victor Krasnykh, Matthew Spear, David Curiel, Roberto Manservigi, Xandra Breakefield (2003). Amplicon Vector Engineered for Specific Binding to Pseudo His-Tag Receptor. In: International Herpesvirus Workshop 2003. Madison (USA), 26-31 luglio 2003

 

Grandi P. Binding of HSV-1 vectors to a specific cell surface receptor. Can we image the infection process in vivo? Boston, Harvard Medical School, Molecular Neurogenetics Dept. 12 March 2004

 

Grandi P. Oncolytic vectors: new strategies of tumor retargeting and imaging. University of Ferrara, Italy, 17 May 2004

 

 

GRANDI P., Trevor McKee, Juliet L. Fernandez, Rakesh K. Jain, Xandra Breakefield (2004). New strategy to improve tumor infectibility of HSV-1 vectors in vivo. In: International Herpesvirus Workshop 2004. Reno, Nevada, USA, July 2004

 

Oehmig, Schuback D., GRANDI P., Fraefel C., Breakefield X (2004). Delivery of AAV REP proteins as VP16-REP fusion proteins in HSV-1 virions. In: International Herpesvirus Workshop 2004. Reno (Nevada-USA), July 25 - Friday, July 30

 

GRANDI P., Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO (2004). HSV-1 virions engineered for specific binding to cell surface receptors. MOLECULAR THERAPY, ISSN: 1525-0016

 

 

GRANDI P. (2004). Binding of HSV-1 vectors to a specific cell surface receptor. Can we image the infection process in vivo? , Invited speaker. University of Zurich, Switzerland

 

Grandi P. Novel strategies for enhanced cancer therapy using HSV vectors. University of Pittsburgh, 13 December 2004

 

GRANDI P. (2005). Binding of HSV-1 vectors to New Strategy to Improve Imaging and Retargeting of HSV-1 Vectors, Invited Speaker.American Society of Gene, Therapy, St. Louis, MO

 

GRANDI P., McKee T, Mok W, Fernandez J, Breakefield X, Jain RK (2005). New Strategy To Improve Imaging and Retargeting of HSV-1 Vectors . MOLECULAR THERAPY, ISSN: 1525-0024

 

GRANDI P., Trevor McKee, Juliet L. Fernandez, Rakesh K. Jain, Xandra Breakefield (2005). In vivo imaging of collagnease-enhanced hsv oncolytic vector destruction of solid tumors. In: International Herpesvirus Workshop 2005 Turku, Finland, 30th July- 4th August

 

GRANDI P. (2005). In vivo imaging of collagnease-enhanced hsv oncolytic vector destruction of solid tumors. , Best Oral presentation award: International Herpesvirus Workshop, Turku, Finland

 

Trevor McKee, GRANDI P., Wilson Mok George Alexandrakis Yves Boucher, Xandra O. Breakefield, Rakesh K. Jain (2005). Degradation of fibrillar collagen in solid tumors improves the efficacy of oncolytic viral therapy. In: BMES. baltimore, September 28 - October 1, 2005

 

 

GRANDI P. (2006). Novel Strategies for enhancing Cancer Therapy using HSV Oncolytic Vectors. , Invited Speaker. Xi’an Jiaotong , University Medical School, China

 

 

GRANDI P. (2006). Novel Strategies for enhancing Cancer Therapy using HSV Oncolytic Vectors. . In: Cancer Molecular Diagnosis and Gene Therapy International Symposium, 2006. Xi'an, China, 22-23 October 2006

 

Li H, Krisky D, GRANDI P., Baskaran R, Glorioso J (2006). HSV-1 ICP0 enhance viral growth through activation of Chk2 nad Induction of G2 arrest. In: International Herpesvirus Workshop . Seattle, 22-28 July 2006

 

GRANDI P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M (2006). Targeting HSV-1 virions for specific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. MOLECULAR THERAPY, ISSN: 1525-0024

 

Glorioso JC, GRANDI P., Krisky D, Goins W, Goss J, Fink DF (2006). HSV gene vectors and treatment of chronic pain and cancer. JOURNAL OF NEUROIMMUNOLOGY, ISSN: 0165-5728

 

GRANDI P., Fernandez J, Szentirmai O, Carter R, Breakefield XO (2006). Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells. MOLECULAR THERAPY, ISSN: 1525-0024

 

BOZAC A, BERTO E, VASQUEZ F, GRANDI P., CAPUTO A, MANSERVIGI R, ENSOLI B, P. MARCONI (2006). Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. VACCINE, vol. 24(49-50); p. 7148-7158, ISSN: 0264-410X

 

GRANDI P. (2007). Design and application of HSV oncolytic vectors for treatment of brain tumors, Invited Speaker Conference: Oncolytic Viruses as Cancer Therapeutics. The 4th International Conference (Arizona-USA), March 14-17, 2007

 

GRANDI P., Forero A., Niranjan A, Fellows W, Okada H, Klinkenberg D, Krisky D, Glorioso J. (2007). Design of ICP0 Deficient HSV Oncolytic Vectors for Treatment of Glioblastoma. MOLECULAR THERAPY, ISSN: 1525-0016

 

GRANDI P., Forero A, Niranjan A. Fellows, W., Goins W., Okada, H., Klinkenberg, D, Krisky, D. and Glorioso, JC. (2007). Role of IDO on HSV oncolytic vectors activity. JOURNAL OF NEUROVIROLOGY, ISSN: 1355-0284

 

GRANDI P. (2007). Novel Strategies for Enhancing Cancer Therapy using HSV Oncolytic Vectors. , Invited Speaker: The Clinical Oncology Grand Rounds, UPCI

 

GRANDI P., Forero A, Niranjan Fellows W, Goins W, Okada H, Klinkenberg D, Krisky D, Glorioso JC (2007). Design of ICP0 Deficient Oncolytic HSV vectors for treatment of Glioblastoma. In: IHW (International Herpesvirus Workshop). Asheville, North Carolina (USA) , July 7-12, 2007

 

GRANDI P. (2007). New Oncolytic HSV vectors for treatment of Glioblastoma. , Invited Speaker. 10th ASGT. May 30-June 3, 2007, Seattle, Washington, USA.

 

GRANDI P. (2007). Novel Strategies for Enhancing Cancer Therapy Using HSV Oncolytic Vectors , Invited Speaker. Korea Institue of Radiological and Medical Sciences November 29, 2007, Seoul, South Korea

 

GRANDI P. (2007). Role of IDO on HSV oncolytic vectors activity. , Invited Speaker. 8th International Symposium on NeuroVirology.San Diego October 29th- November 2nd, 2007

 

Forero A, Niranjan A, Fellows W, Okada H, Hiba C, Hong CS, Glorioso JC, GRANDI P. (2008). Effect of Indoleamine-2,3-Dioxygenase (IDO) on Replication of Oncolytic HSV Vectors in Glioma Cells. MOLECULAR THERAPY, ISSN: 1525-0016

 

GRANDI P. (2008). Effect of IDO on replication of oncolytic HSV vectors in glioma cells. , Invited Speaker: 9th International Congress of Neuroimmunology , Fort Worth, Texas 26-30 October

 

GRANDI P. (2008). Innate Immune Responses Limit HSV Oncolysis. , Invited Speaker. Gordon Conference, The Science of Viral Vector, March 2-7, 2008, Ventura, California

 

GRANDI P. (2008). Vector, March 2-7, 2008, Ventura, California Invited Speaker- Targeted delivery of glycine receptors to peripheral neurons as treatment for pain , Universidad Montevideo-Uruguay

 

Hong CH, Forero A, Niranjan A, Pollack I, GRANDI P. (2008). Methods to Enhance the Spread and Onclytic Activity of HSV Vectors in GBM Therapy. . In: IHW . Estoril, Portugal, July 27 - August 1, 2008

 

Marzulli M, Mazzacurati L, Uchida H, Justus Cohen, Reinhart B, Hong CH, Joseph Glorioso J, GRANDI P. (2010). Design and application of a new HSV vector for treatment of Glioblastoma. In: European Society Gene and cell therapy

 

Marzulli M, Mazzacurati L, Uchida H, Cohen J, Reinhart B, Hong CH, Glorioso J, GRANDI P. (2010). Advanced Oncolity vectors for treatment of brain tumors. JOURNAL OF NEUROVIROLOGY, ISSN: 1355-0284

 

GRANDI P. (2011). MicroRNA control of HSV-1 replication for the treatment of glioblastoma multiforme. , Invited Speaker. IHW 2011, July 24-28, Gdansk, Polland

 

Mazzacurati L, Marzulli M, Reinhart B, Cohen J, GLorioso J, GRANDI P. (2011). MicroRNA control of HSV-1 replication for the treatment of glioblastoma multiforme. In: IHW 2011 Gdansk, Polland

 

 

GRANDI P. (2011). Targeting oncolytic HSV replication to brain tumors. . In: Oncolytic viruses as a cancer therapeutics. March 16-19, 2011, Las Vegas, NV

 

GRANDI P., GLorioso J (2011). Glioblastoma restricted oHSV replication based on vector retargeting and microRNA control of essential virus gene expression. In: 15th International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections. venice, October 13-15, 2011.

 

Mazzacurati L, Marzulli M, Reinhart B, Cohen J, Glorioso JC, GRANDI P. (2011). MicroRNA Control of HSV-1 Replication for the Treatment of Glioblastoma Multiforme. MOLECULAR THERAPY, ISSN: 1525-0024

 

GRANDI P. (2011). Targeting oncolytic HSV replication to brain tumors. , Invited Speaker. Oncolytic viruses as a cancer therapeutics. March 16-19, 2011, Las Vegas, NV

 

GRANDI P. (2011). HSV-1 based controlled oncolytic vector for the treatment of glioblastoma multiforme.ASCGT, May 19-23, 2011 Seattle, WA

 

Marzulli M, Mazzacurati L, Reinhart B, Glorioso JC, Cohen J, GRANDI P. (2012). A New Class of Glioblastoma Restricted oHSV Replication Based on microRNA Control of Essential Virus Gene Expression. MOLECULAR THERAPY, ISSN: 1525-0016

 

Uchida H, Marzulli M, Chan J, Mazzacurati M, Goins W, Zhang M, Hong C-S, Nakashima H, Haseley A, Yoo J-Y, Kaur B, Chiocca A, GRANDI P., Cohen J, Glorioso JC (2012). Efficient HSV-1 Retargeting by Modification of Glycoproteins D and B. MOLECULAR THERAPY, ISSN: 1525-0024

 

 

Miyagawa Y, Cohen J, Simonato M, GRANDI P., Glorioso JC (2012). DEVELOPMENT OF AN EFFICIENT AND VERSATILE HERPES SIMPLEX VIRUS VECTOR SYSTEM FOR CELLULAR REPROGRAMMING. In: International Society for Stem Cell Research, 10th annual meeting . yokohama Japan , june 13-16, 2012

 

GRANDI P. (2012). Efficient HSV-1 Retargeting by Modification of Glycoproteins D and B , Oral presentation. ASGCT 15th Annual Meeting, May 16-19, 2012 in Philadelphia, PA, USA

 

GRANDI P. (2012). Development of a new class of tumor targeted oncolytic HSV vectors, Invited Speaker. September 19 - 22, 2012. Orvieto

 

Highly Selective HSV Virotherapy of Glioblastoma by Combining EGFR-Tumor Targeting and microRNA Blockade of Virus Replication in Normal Brain

ASGCT 16thAnnual Meeting, Salt Lake City, Utah, May 15 – 18, 2013

 

Development of an Efficient and Versatile Herpes Simplex Virus Vector System for Cellular Reprogramming. ASGCT 16thAnnual Meeting, Salt Lake City, Utah, May 15 – 18, 2013

 

GRANDI P. Highly selective HSV virotherapy for glioblastoma. The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec City, Quebec, Canada June 15 – 18, 2013

 

GRANDI P. miRNA- controlled HSV-based vectors. “MicroRNA: from basic research to therapeutic applications”, Ferrar, Italy 16 - 17 september 2013